Ann: Alcidion Appendix 4C - quarterly, page-20

Good points composer, and thanks for reminding me about the significant R&D investment from Malcolm and Ray prior to listing. I don't have the figures handy but it was certainly substantial in dollar terms and one of the appealing aspects of ALC.

Should be in the prospective, I recall it being estimated to be in excess of 10 million to reach the stage of sophistication that ALC are at with MIYA clinical decision support system, etc. I would have thought this alone should equate to a SP much higher than this - think how many speculative companies are using shareholders to fund the research rather than the commercialisation?